纳武利尤单抗联合伊匹木单抗用于广泛期小细胞肺癌维持治疗:CheckMate 451研究
CheckMate 451是一项双盲III期试验,评估纳武利尤单抗联合伊匹木单抗及纳武利尤单抗单药对比安慰剂在广泛期小细胞肺癌一线化疗后未进展患者中的维持治疗。中位OS 9.2 vs 9.6个月)。联合组3-4级治疗相关不良事件发生率为52.2%。
要点
- 纳武利尤单抗联合伊匹木单抗维持治疗未显著改善广泛期小细胞肺癌患者OS。
- 联合组3-4级治疗相关不良事件发生率高达52.2%,单药组为11.5%,安慰剂组为8.4%。
- 肿瘤突变负荷≥13个突变/兆碱基的患者中观察到联合治疗OS获益趋势。
核心结论
- 对于一线化疗后未进展的广泛期小细胞肺癌患者,纳武利尤单抗联合伊匹木单抗维持治疗未显著延长总生存期。
- 未观察到新的安全性信号。
研究设计与样本
- 双盲III期随机对照试验,834例广泛期小细胞肺癌患者按1:1:1随机分配至纳武利尤单抗联合伊匹木单抗组、纳武利尤单抗单药组或安慰剂组。
- 患者为ECOG体能状态0-1且一线化疗≤4周期后未进展者,治疗≤2年或直至疾病进展或不可耐受毒性。
- 主要终点为联合组对比安慰剂的总生存期,次要终点按层级检验。
主要发现
- 纳武利尤单抗单药对比安慰剂OS的HR为0.84(95%CI 0.69-1.02),中位OS为10.4个月。
- 联合组对比安慰剂无进展生存期HR为0.72(95%CI 0.60-0.87),纳武利尤单抗单药组为0.67(95%CI 0.56-0.81)。
- 肿瘤突变负荷≥13个突变/兆碱基的患者中观察到联合治疗OS获益趋势。
- 3-4级治疗相关不良事件发生率:联合组52.2%,纳武利尤单抗单药组11.5%,安慰剂组8.4%。
临床怎么用
- 不推荐纳武利尤单抗联合伊匹木单抗作为广泛期小细胞肺癌一线化疗后的标准维持治疗。
- 联合方案毒性显著,临床决策需权衡风险获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In extensive-disease small-cell lung cancer (ED-SCLC), response rates to first-line platinum-based chemotherapy are robust, but responses lack durability. CheckMate 451, a double-blind phase III trial, evaluated nivolumab plus ipilimumab and nivolumab monotherapy as maintenance therapy following first-line chemotherapy for ED-SCLC. METHODS: Patients with ED-SCLC, Eastern Cooperative Oncology Group performance status 0-1, and no progression after ≤ 4 cycles of first-line chemotherapy were randomly assigned (1:1:1) to nivolumab 1 mg/kg plus ipilimumab 3 mg/kg once every 3 weeks for 12 weeks followed by nivolumab 240 mg once every 2 weeks, nivolumab 240 mg once every 2 weeks, or placebo for ≤ 2 years or until progression or unacceptable toxicity. Primary end point was overall survival (OS) with nivolumab plus ipilimumab versus placebo. Secondary end points were hierarchically tested. RESULTS: Overall, 834 patients were randomly assigned. The minimum follow-up was 8.9 months. OS was not significantly prolonged with nivolumab plus ipilimumab versus placebo (hazard ratio [HR], 0.92; 95% CI, 0.75 to 1.12; P = .37; median, 9.2 v 9.6 months). The HR for OS with nivolumab versus placebo was 0.84 (95% CI, 0.69 to 1.02); the median OS for nivolumab was 10.4 months. Progression-free survival HRs versus placebo were 0.72 for nivolumab plus ipilimumab (95% CI, 0.60 to 0.87) and 0.67 for nivolumab (95% CI, 0.56 to 0.81). A trend toward OS benefit with nivolumab plus ipilimumab was observed in patients with tumor mutational burden ≥ 13 mutations per megabase. Rates of grade 3-4 treatment-related adverse events were nivolumab plus ipilimumab (52.2%), nivolumab (11.5%), and placebo (8.4%). CONCLUSION: Maintenance therapy with nivolumab plus ipilimumab did not prolong OS for patients with ED-SCLC who did not progress on first-line chemotherapy. There were no new safety signals.
引用
- Owonikoko TK, Park K, Govindan R, et al. Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451. J Clin Oncol. 2021. PMID: 33683919. doi:10.1200/JCO.20.02212
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。